Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.


PURPOSE This phase II study evaluated the efficacy and safety of ixabepilone as neoadjuvant therapy for invasive breast cancer not amenable to breast conservation surgery. Gene expression studies were undertaken using genes that were identified as potentially associated with sensitivity/resistance to ixabepilone in prior preclinical investigations… (More)
DOI: 10.1200/JCO.2007.14.2646


  • Presentations referencing similar topics